Tigress Financial analyst Ivan Feinseth initiated coverage with a Buy rating on Royalty Pharma (RPRX – Research Report) today and set a price target of $50.00. The company’s shares closed last Friday at $38.40.
According to TipRanks.com, Feinseth is a top 100 analyst with an average return of 20.0% and a 70.7% success rate. Feinseth covers the Technology sector, focusing on stocks such as Alphabet Class A, Microsoft, and Facebook.
Currently, the analyst consensus on Royalty Pharma is a Moderate Buy with an average price target of $50.00.
The company has a one-year high of $53.23 and a one-year low of $34.80. Currently, Royalty Pharma has an average volume of 1.99M.
Based on the recent corporate insider activity of 64 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RPRX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
New York-based Royalty Pharma Plc is a biopharmaceutical company, which is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry.